ClinicalTrials.gg
Status unknownNCT04337567Updated Apr 7, 2020

Radiofrequency Ablation Versus Balloon Cryoablation in Elderly Patients With Atrial Fibrillation

An interventional study of radiofrequency ablation and ballon cryoablation in Atrial Fibrillation, sponsored by Vivantes Netzwerk für Gesundheit GmbH. Status unknown at 1 site in Germany. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2020-04-07.

Sponsored by Vivantes Netzwerk für Gesundheit GmbH · Not applicable, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Apr 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
75 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 417 studies in Atrial Fibrillation with a site in Germany — 60 open to participants now, 88 under way, 4 of them phase 3. Atrial Fibrillation · Germany.

Planned enrollment
225th of 284
80 · median 200
Started
2020
with 21 others
No phase
166 of 417
31 open now
Registered
286th of 417
by date

Among the 417 studies in Atrial Fibrillation with a site in Germany, this one is the 225th largest by planned enrollment of the 284 interventional ones that give a count, is one of 22 that started in 2020, is one of 166 with no phase, and was the 286th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

60 of the 417 studies in Atrial Fibrillation with a site in Germany are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 75 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 417 studies in Atrial Fibrillation with a site in Germany, or all of them as a file.
02

Study summary

This study compares the procedural characteristics and effectivity of radiofrequency ablation and cryoablation in patients with atrial fibrillation that are 75 years or older.

Read the detailed description

Radiofrequency and cryoballon ablation have been shown to be comparable to each other in terms of safety and effectivity in patients with atrial fibrillation. However, elderly patients have been underrepresented in the previous studies. The number of older patients with atrial fibrillation is high and the number of who undergo an ablation procedure for atrial fibrillation increases steadily. This prospective randomized trial compares the effectivity (recurrency of atrial arrhythmias) and periprocedural characteristics of the two established ablation methods in patients who are 75 years or older.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

Keywords

  • ablative treatment of atrial fibrillation
  • ballon cryoablation
  • radiofrequency ablation
  • elderly patients
04

Who can participate

Ages eligible
75 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with recurrent symptomatic paroxysmal or persistent atrial fibrillation
  • At the day of their inclusion in the study the patients have to have completed the 75th year of life

Exclusion criteria

Exclusion Criteria:

  • Dementia
  • Presence of left atrial thrombus
  • Left atrial volume> 50 ml/m²
  • Renal failure (≤ 30 ml/min)
  • Comorbidity with an expected survival of 12 months or less.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Active comparator
    Patients over 75 years_RF ablation

    Patients randomized to receive pulmonary vein isolation by means of radiofrequency ablation.

    Procedure: radiofrequency ablation

  • Active comparator
    Patients over 75 years_ballon cryoablation

    Patients randomized to receive pulmonary vein isolation by means of ballon cryoablation.

    Procedure: ballon cryoablation

Interventions

  • Procedureradiofrequency ablation

    ablative treatment as allocated to radiofrequency ablation

  • Procedureballon cryoablation

    ablative treatment as allocated to ballon cryoablation

06

What researchers measure

Primary outcomes

  1. atrial arrhythmia recurrence

    Number of Participants with recurrence of any atrial arrhythmia with a duration of 30 sec or longer 12 months after the ablative treatment

    Time frame: 1 year

Secondary outcomes

  1. procedural duration

    Duration of the whole procedure \[min\] inclusive preparation (from entrance to the EP lab till exit from the EP lab)

    Time frame: periprocedural

  2. time to wake-up after propofol withdrawal

    Time from withdrawal of propofole till patient awake and fully oriented (time, place, person)

    Time frame: periprocedural

  3. contrast medium dosis

    Amount of contrast medium used

    Time frame: periprocedural

  4. Propofoldosis

    Propofoldosis needed for sedation

    Time frame: periprocedural

  5. groin complications

    Number of Participants in each randomisation arm with groin complications (hematoma, av fistel, Aneuryma spurium, infection).

    Time frame: up to 3 months after dismission from the hospital

  6. Neurological complications

    Number of Participants in each randomisation arm with transient ischemic attack, cerebral insult, cerebral haemorrhage

    Time frame: 1 year

  7. vascular complications

    Number of Participants in each randomisation arm with deep vein thrombosis, peripheral embolism.

    Time frame: 1 year

  8. duration of hospital staying [days]

    duration of hospital staying: from admission till discharge in days

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2020 (actual). Primary completion is estimated for Jan 2022, 22 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 22 months is below that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2020
First posted
Apr 7, 2020
StartActual
Mar 1, 2020
Primary completionEst.
Jan 31, 2022
CompletionEst.
Jan 31, 2024
Last update
Apr 7, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04337567
Lead sponsor
Vivantes Netzwerk für Gesundheit GmbH
Responsible party
Charalampos Kriatselis (Principal Investigator, Vivantes Netzwerk für Gesundheit GmbH) — Principal investigator
First posted
Apr 7, 2020
Start date
Mar 1, 2020
Primary completion
Jan 31, 2022 (estimated)
Completion
Jan 31, 2024 (estimated)
Last update
Apr 7, 2020

Study contacts

Charalampos Kriatselis, MD
Contact
charalampos.kriatselis@vivantes.de
0049 30 15140663741
Michael Distler, MD
Contact
michael.distler@vivantes.de
0049 30 130 142014
Charalampos Kriatselis, MD
principal investigator · Vivantes Clinic Neukölln

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion